Gerber Kawasaki Wealth & Investment Management Purchases 2,139 Shares of Eli Lilly and Company $LLY

Gerber Kawasaki Wealth & Investment Management raised its position in Eli Lilly and Company (NYSE:LLY) by 12.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 19,169 shares of the company’s stock after buying an additional 2,139 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in Eli Lilly and Company were worth $22,180,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of LLY. BlackRock Inc. boosted its holdings in shares of Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp increased its stake in shares of Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares during the period. Bank of America Corp DE acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Eli Lilly and Company by 1.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,408.68 on Wednesday. The firm has a market capitalization of $1.33 trillion, a P/E ratio of 45.72, a PEG ratio of 1.77 and a beta of 0.40. The stock has a fifty day moving average price of $1,204.03 and a 200 day moving average price of $1,095.92. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,449.68. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period last year, the company earned $7.02 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 35.61 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LLY. Bank of America restated a “buy” rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a research report on Friday. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Cantor Fitzgerald increased their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an “overweight” rating in a research note on Monday. BMO Capital Markets reissued an “outperform” rating and issued a $1,650.00 price target on shares of Eli Lilly and Company in a report on Friday. Finally, Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target for the company in a report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,404.14.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s third-quarter revenue of $24.4 billion and EPS of $7.48 topped estimates, while revenue rose 38.6% year over year. The company raised its 2026 revenue outlook to $91 billion–$92 billion, reinforcing the demand-driven growth case. Raised Guidance Altering The Investment Case For Eli Lilly Stock?
• Positive Sentiment: Mounjaro and Zepbound remain key growth engines. Retatrutide also showed encouraging Phase 3 results versus Ozempic 2 mg in a diabetes trial, strengthening Lilly’s competitive position and future pipeline prospects. Eli Lilly Just Gained 22% in a Month
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,600 from $1,440 and maintained an “overweight” rating, reflecting optimism about the company’s outlook.
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale reduced her direct holdings by 54.72%, though planned insider transactions may carry less information than discretionary sales. SEC Form 4 filing
• Negative Sentiment: Some commentary warns that expectations may be ahead of sustainable growth: revenue growth could moderate, realized drug prices are reportedly falling, and some recent revenue contributions may not recur. A high valuation makes the shares more sensitive to any slowdown. Eli Lilly: Priced For Acceleration, Reporting Deceleration
• Negative Sentiment: Pipeline setbacks and dropped drug candidates outside the GLP-1 franchise raise questions about whether Lilly can broaden growth beyond its current blockbuster products. Lilly’s R&D whirlwind

Insider Buying and Selling

In related news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 18,500 shares of company stock valued at $22,970,770. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.